OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ILM1K58

Medios AG

PharmaceuticalsVerified

Medios AG has a debt-to-equity ratio of 0.39 and a current ratio of 1.9, indicating a relatively balanced capital structure with moderate liquidity. However, the company's cash and equivalents are negative at -1,000 EUR, which raises concerns about its short-term liquidity position. The company's free cash flow of 44,934,000 EUR suggests it is generating positive cash from operations, but the negative net cash position indicates that the company may need to manage its working capital or debt obligations carefully. In terms of profitability, Medios AG has a return on equity of 2.99% and a return on assets of 1.7%, which are below the industry median for pharmaceutical companies. The company's operating income of 46,196,000 EUR and net income of 15,365,000 EUR indicate that it is profitable, but the low return metrics suggest that the company may not be utilizing its equity and assets as efficiently as its peers. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification could expose the company to higher risk if demand in its primary therapeutic areas declines or if regulatory changes impact its operations. Looking at the company's growth trajectory, the available data does not provide specific revenue growth projections for the current or next fiscal year. However, the company's operating cash flow of 52,273,000 EUR and free cash flow of 44,934,000 EUR suggest that it has the financial capacity to invest in research and development or expand its product portfolio. The risk assessment for Medios AG indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the need for the company to maintain sufficient liquidity to meet its obligations. The company's capital expenditure of -8,291,000 EUR suggests that it is not currently investing in new long-term assets, which could affect its long-term growth potential. Recent events related to Medios AG include analyst estimates for the company's stock price, with a mean price target of 23.00 EUR and a median price target of 24.00 EUR. The mean recommendation from analysts is 1.40, indicating a generally positive outlook, with three strong-buy ratings and two buy ratings.

30-day price · ILM1K(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyMedios AG
TickerILM1K.DE
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Medios AG is a pharmaceutical company that develops and commercializes prescription drugs, primarily in the therapeutic areas of oncology and rare diseases.

Classification. Medios AG is classified in the Pharmaceuticals industry under the Healthcare economic sector with a confidence level of 0.92.

Medios AG has a debt-to-equity ratio of 0.39 and a current ratio of 1.9, indicating a relatively balanced capital structure with moderate liquidity. However, the company's cash and equivalents are negative at -1,000 EUR, which raises concerns about its short-term liquidity position. The company's free cash flow of 44,934,000 EUR suggests it is generating positive cash from operations, but the negative net cash position indicates that the company may need to manage its working capital or debt obligations carefully. In terms of profitability, Medios AG has a return on equity of 2.99% and a return on assets of 1.7%, which are below the industry median for pharmaceutical companies. The company's operating income of 46,196,000 EUR and net income of 15,365,000 EUR indicate that it is profitable, but the low return metrics suggest that the company may not be utilizing its equity and assets as efficiently as its peers. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification could expose the company to higher risk if demand in its primary therapeutic areas declines or if regulatory changes impact its operations. Looking at the company's growth trajectory, the available data does not provide specific revenue growth projections for the current or next fiscal year. However, the company's operating cash flow of 52,273,000 EUR and free cash flow of 44,934,000 EUR suggest that it has the financial capacity to invest in research and development or expand its product portfolio. The risk assessment for Medios AG indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the need for the company to maintain sufficient liquidity to meet its obligations. The company's capital expenditure of -8,291,000 EUR suggests that it is not currently investing in new long-term assets, which could affect its long-term growth potential. Recent events related to Medios AG include analyst estimates for the company's stock price, with a mean price target of 23.00 EUR and a median price target of 24.00 EUR. The mean recommendation from analysts is 1.40, indicating a generally positive outlook, with three strong-buy ratings and two buy ratings.
Key takeaways
  • Medios AG has a balanced capital structure with a debt-to-equity ratio of 0.39 and a current ratio of 1.9.
  • The company's return on equity and return on assets are below the industry median, indicating lower efficiency in utilizing equity and assets.
  • The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
  • Analysts have a generally positive outlook on Medios AG, with a mean price target of 23.00 EUR and a mean recommendation of 1.40.
  • The company has a medium liquidity risk and a low dilution risk, but its negative net cash position requires careful management.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyEUR
Revenue$2.08B
Gross profit$199.0M
Operating income$46.2M
Net income$15.4M
R&D
SG&A
D&A
SBC
Operating cash flow$52.3M
CapEx-$8.3M
Free cash flow$44.9M
Total assets$903.0M
Total liabilities$388.8M
Total equity$514.2M
Cash & equivalents-$1.0k
Long-term debt$201.8M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$514.2M
Net cash-$201.8M
Current ratio1.9
Debt/Equity0.4
ROA1.7%
ROE3.0%
Cash conversion3.4%
CapEx/Revenue-0.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricILM1KActivity
Op margin2.2%7.7% medp25 -2.4% · p75 15.5%below median
Net margin0.7%5.9% medp25 -3.8% · p75 12.8%below median
Gross margin9.6%45.5% medp25 31.1% · p75 62.9%bottom quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-0.4%-7.0% medp25 -14.9% · p75 -3.2%top quartile
Debt / equity39.0%25.0% medp25 3.8% · p75 63.3%above median
Observations
IR observations
Mean price target23.00 EUR
Median price target24.00 EUR
High price target26.00 EUR
Low price target18.00 EUR
Mean recommendation1.40 (1=strong buy, 5=strong sell)
Strong-buy count3.00
Buy count2.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate1.18 EUR
Last actual EPS0.61 EUR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-23 06:25 UTC#77b0373d
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 05:01 UTCJob: 6be36601